Woodley Farra Manion Portfolio Management Inc. Grows Stock Holdings in AbbVie Inc. $ABBV

Woodley Farra Manion Portfolio Management Inc. lifted its position in shares of AbbVie Inc. (NYSE:ABBV) by 358.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,746 shares of the company’s stock after purchasing an additional 11,527 shares during the period. Woodley Farra Manion Portfolio Management Inc.’s holdings in AbbVie were worth $3,414,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Ellenbecker Investment Group lifted its stake in AbbVie by 0.8% in the third quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock worth $1,235,000 after acquiring an additional 44 shares during the period. Security National Bank of Sioux City Iowa IA boosted its position in AbbVie by 0.3% during the 3rd quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock valued at $3,562,000 after acquiring an additional 45 shares in the last quarter. Matthew Goff Investment Advisor LLC raised its position in shares of AbbVie by 0.3% in the 3rd quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock worth $4,066,000 after acquiring an additional 45 shares in the last quarter. Centennial Wealth Advisory LLC boosted its position in shares of AbbVie by 2.2% during the third quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock valued at $484,000 after purchasing an additional 45 shares in the last quarter. Finally, Willner & Heller LLC grew its stake in AbbVie by 0.6% in the third quarter. Willner & Heller LLC now owns 7,596 shares of the company’s stock worth $1,759,000 after purchasing an additional 46 shares during the period. Institutional investors own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on ABBV. JPMorgan Chase & Co. raised their target price on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. Citigroup dropped their target price on AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 27th. BMO Capital Markets reaffirmed an “outperform” rating and set a $258.00 price target on shares of AbbVie in a report on Thursday, January 15th. Evercore cut their price objective on AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research report on Wednesday, February 4th. Finally, DZ Bank lowered AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target on the stock. in a report on Tuesday, November 4th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $252.79.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA approves the all‑oral combination of VENCLEXTA® (venetoclax) and acalabrutinib for previously untreated CLL — a first‑in‑class, fixed‑duration regimen supported by Phase 3 AMPLIFY data. This expands AbbVie’s addressable hematology market, could drive incremental high‑margin sales and offers a differentiated product profile (time off therapy). U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
• Positive Sentiment: Coverage noting the FDA approval frames the combo as potentially setting a new standard for slow‑growing blood cancers, highlighting improved three‑year outcomes versus chemo and the commercial upside if physicians adopt an oral, fixed‑duration approach. FDA Approval For AbbVie/AstraZeneca’s Combination Treatment Could Set New Standard For Slow Growing Blood Cancer
• Positive Sentiment: Board declared a quarterly cash dividend of $1.73/share (ex‑div April 15) — reinforces AbbVie’s income profile (Dividend King status) and supports the stock’s appeal to yield‑focused investors. AbbVie Declares Quarterly Dividend
• Positive Sentiment: VOLITE skin‑quality trial completion update suggests progress in AbbVie’s dermatology pipeline (potential incremental indications/label expansion), a longer‑term earnings catalyst if follow‑up data are positive. AbbVie’s VOLITE Skin Quality Trial Completion: What It Means for ABBV Investors
• Neutral Sentiment: Company launched a healthcare‑innovation podcast (“The Persistence Lab”) — useful for brand/ stakeholder engagement but unlikely to move near‑term fundamentals. AbbVie heads to ‘The Persistence Lab’ in new podcast highlighting healthcare innovation
• Neutral Sentiment: Investor pieces encouraging a reassessment of AbbVie’s post‑Humira pipeline highlight progress but are mixed on timing and magnitude of offset to Humira’s legacy revenues — suggests potential upside if execution continues but not guaranteed. Should AbbVie’s (ABBV) Post-Humira Pipeline Progress Prompt a Fresh Look From Investors?
• Negative Sentiment: Evercore trimmed its price target slightly (from $232 to $228) and flagged that Tremfya’s market‑share gains may not translate into strong long‑term earnings growth — this analyst caution can weigh on sentiment given AbbVie’s recent valuation and investor focus on growth after Humira. Evercore Notes AbbVie Inc.’s (ABBV) Tremfya Gains Market Share, But Future Earnings Growth May Be Limited

AbbVie Stock Performance

NYSE:ABBV traded up $0.73 during mid-day trading on Friday, hitting $225.08. 415,725 shares of the company’s stock traded hands, compared to its average volume of 7,292,311. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The company has a market capitalization of $397.80 billion, a P/E ratio of 95.57, a P/E/G ratio of 0.80 and a beta of 0.35. The company has a fifty day moving average of $224.01 and a 200 day moving average of $221.70.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The business had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same period in the previous year, the firm posted $2.16 earnings per share. The business’s revenue for the quarter was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio is presently 293.22%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.